Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents.
about
Management of bleeding in patients treated with direct oral anticoagulantsSteps to consider in the approach and management of critically ill patient with spontaneous intracerebral hemorrhageClinical review: Traumatic brain injury in patients receiving antiplatelet medicationSafety of new oral anticoagulant drugs: a perspectiveProperdin: a tightly regulated critical inflammatory modulatorPharmacology of anticoagulants used in the treatment of venous thromboembolismRisk analysis of new oral anticoagulants for gastrointestinal bleeding and intracranial hemorrhage in atrial fibrillation patients: a systematic review and network meta-analysis.Probing the coagulation pathway with aptamers identifies combinations that synergistically inhibit blood clot formation.European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.Hemostatic resuscitation in postpartum hemorrhage - a supplement to surgery.Facile chemoenzymatic synthesis of biotinylated heparosan hexasaccharide.Nucleic acid scavengers inhibit thrombosis without increasing bleeding.Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults.Outcomes of severe sepsis and septic shock patients on chronic antiplatelet treatment: a historical cohort study.Allosterism-based simultaneous, dual anticoagulant and antiplatelet action: allosteric inhibitor targeting the glycoprotein Ibα-binding and heparin-binding site of thrombin.Management of bleeding in patients receiving conventional or new anticoagulants: a practical and case-based approach.New oral anticoagulants in atrial fibrillation: a reappraisal of trial results looking at absolute figures.Clinical management of rivaroxaban-treated patients.New oral anticoagulants in non-valvular atrial fibrillation.Prophylaxis and treatment of venous thromboembolism in the critically ill.Novel anticoagulants for stroke prevention in atrial fibrillation: safety issues in the elderly.Competition between low-dose aspirin and other NSAIDs for COX-1 binding and its clinical consequences for the drugs' antiplatelet effects.Monitoring and reversal strategies for new oral anticoagulants.Protein engineering: a new frontier for biological therapeutics.Who, when, and how to reverse non-vitamin K oral anticoagulants.Therapies for Hemorrhagic Transformation in Acute Ischemic Stroke.Direct Oral Anticoagulants in Emergency Trauma Admissions.Coagulation factor XI vaccination: an alternative strategy to prevent thrombosis.Adverse Drug Reactions and Cutaneous Manifestations Associated With Anticoagulation.The European Heart Rhythm Association Practical Guide on the Use of New Oral Anticoagulants in Patients with Non-valvular Atrial Fibrillation - A Brief Summary.Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis.ANMCO Position Paper: the use of non-vitamin K dependent new oral anticoagulant(s) in pulmonary embolism therapy and prevention.Erratum to: Pharmacology of anticoagulants used in the treatment of venous thromboembolism.Intravenous administration of desmopressin acetate to reverse acetylsalicylic acid-induced coagulopathy in three dogs.Management of bleeding in patients taking FXa and FIIa inhibitors.Reversal strategy in antagonizing the P2Y12 -inhibitor ticagrelor.Epicardial catheter ablation for ventricular tachycardia in heparinized patients.Evaluation of dabigatran utilization and risk among hospitalized patients.Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma.
P2860
Q26740258-D9FE864D-6998-44F2-81A1-50486E99C24CQ26799392-D7F51186-EA7C-4C95-A1D9-C645C837E22BQ26830409-0A7E6D17-25A4-47DC-99F3-9B3CB9B31736Q27016072-FBABBB05-80EE-4514-8AD8-9B00E224C5B0Q28069187-4890EBFE-97E5-4B3E-9541-BC6709E74DB0Q28078967-DB909ABD-76D2-4FD0-A193-32F090B21CBCQ33876319-8765187D-1972-4D78-86C5-1B337C9CDEFAQ34052471-71A1D85B-6EE7-4F87-AB0A-3F6DFCEED057Q34651051-D8208D62-4540-4229-ABF7-CE1C37F97827Q35557436-15EB46DC-C691-4AFD-B736-84C08CC9AA8CQ35754841-2C2F64BD-D395-4C77-9BE4-2720BE35B44BQ36167707-E3E3FAB5-4F67-4A48-B102-6E6FAEF99F0CQ36515685-2DB6CD15-D27B-46A4-98DC-526AB660B2F4Q36663432-11DA8887-B89A-4335-9BCF-978D88D0E545Q36788507-5888AB99-C4ED-480C-B852-2463A1D7F7DFQ38049617-698BB8DA-0E1A-4C97-842A-6DBCEFD9DC35Q38068113-5C559F2F-7F4C-4911-B6DA-DE8BFF81CF54Q38081946-539039C2-250B-4850-8F7F-5E4497E70D29Q38105041-FD5631C2-C23C-426E-B5F2-9E98220D8CE7Q38130269-2D25ABC4-AE69-4B2D-8D2B-74A9D2668124Q38155933-51DF4779-069A-4A77-B75F-D97B1A07FF5EQ38259405-8F388560-23D7-47D6-BD3A-B4180200F2A8Q38272325-A432D593-E388-4589-B9DF-1C50F5921AFBQ38286271-901DE1FA-B529-4CA1-8F73-2E6476AA98BFQ38655960-0D9FB084-FD0C-4A5C-AB19-25A53E69BEF1Q38764867-6FEB32DC-C330-45F9-AFC5-F05DAF40B233Q38961751-EFBF0B56-E3FD-4D16-B76E-FFC2FF9B3FC9Q39215603-2A2D00D9-ED8E-4245-B054-FE5B6D4D2B57Q39390373-F459FD19-FFC6-4D4A-9DAE-6F24A5448F52Q40033422-C1E816EF-B817-4F2A-88D6-FBBA93EFA964Q40478828-61B34018-A62B-4D41-A753-8710BCCB82A0Q41118456-98966855-61E0-4443-8B67-EAFC4ECDF9C0Q42387444-AB9F5D6B-4A2F-407D-A8CD-C78EE1CB6EBCQ43498963-7E607CC3-6021-4659-BE30-9E085039D67EQ45007433-98019211-A5A8-452D-B8EA-10D93DA95710Q45276265-5CE9076F-B021-483B-9C72-6656EF33CB09Q50122196-F9F1D87E-3AAF-4D70-A017-3BF8BB1AB743Q50751291-95FE9A59-8382-4331-ACB0-DD62DC0FB280Q53108240-4B519F10-A1C6-4E25-A6B0-FE5DFB913FCA
P2860
Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bleeding risk and reversal str ...... lants and antiplatelet agents.
@en
Bleeding risk and reversal str ...... lants and antiplatelet agents.
@nl
type
label
Bleeding risk and reversal str ...... lants and antiplatelet agents.
@en
Bleeding risk and reversal str ...... lants and antiplatelet agents.
@nl
prefLabel
Bleeding risk and reversal str ...... lants and antiplatelet agents.
@en
Bleeding risk and reversal str ...... lants and antiplatelet agents.
@nl
P2093
P2860
P1476
Bleeding risk and reversal str ...... lants and antiplatelet agents.
@en
P2093
E Eerenberg
P W Kamphuisen
P2860
P304
P356
10.1111/J.1538-7836.2011.04432.X
P577
2011-09-01T00:00:00Z